^
No biomarker
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Squamous Cell Skin Cancer
cemiplimab
Sensitive: A1 - Approval
No biomarker
Squamous Cell Skin Cancer
celecoxib
Resistant: A2 - Guideline
No biomarker
Squamous Cell Skin Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Squamous Cell Skin Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Squamous Cell Skin Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Squamous Cell Skin Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Squamous Cell Skin Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Squamous Cell Skin Cancer
cetuximab
Sensitive: A2 - Guideline
PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C1 - Off-label
CCND1 overexpression
Squamous Cell Skin Cancer
everolimus
Resistant: C3 – Early Trials
MSH6 mutation + MLH1 mutation + MSI-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C4 – Case Studies
TMB-H + PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab + panitumumab
Sensitive: C4 – Case Studies
ERBB3 R135C + TMB-H
Squamous Cell Skin Cancer
nivolumab + lapatinib
Sensitive: C4 – Case Studies
SRC amplification
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C4 – Case Studies
TP53 mutation
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C4 – Case Studies
BRCA2 deletion
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C4 – Case Studies
NGFR overexpression
Squamous Cell Skin Cancer
5-fluorouracil
Sensitive: D – Preclinical
NGFR overexpression
Squamous Cell Skin Cancer
cisplatin
Sensitive: D – Preclinical